Patrick I. Borgen, MD
The rapid developments regarding coronavirus 2019 (COVID-19) have raised the question of how this virus could impact patients with cancer who are receiving immunosuppressive therapies.
Adam M. Brufsky, MD, PhD
Beyond Borgen, several faculty who were on site at the 2020 MBCC Conference touched upon COVID-19, including:
- Adam M. Brufsky, MD, PhD, professor of medicine and associate chief in the Division of Hematology/Oncology, co-director of the Comprehensive Breast Cancer Center, and associate director of Clinical Investigation at the University of Pittsburgh Medical Center Hillman Cancer Center;
- Debu Tripathy, MD, professor and chairman of the Department of Breast Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center;
- Enrique Soto Pérez de Celis, MD, MSc, a geriatric oncologist and researcher in the Department of Geriatrics at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City, Mexico;
- Aditya Bardia, MD, MPH, director of Precision Medicine at the Center for Breast Cancer and founding director of the Molecular and Precision Medicine Metastatic Breast Cancer Clinic at Massachusetts General Hospital Cancer Center, and assistant professor of medicine at Harvard Medical School;
- Sara A. Hurvitz, MD, associate professor at the David Geffen School of Medicine, University of California, Los Angeles (UCLA), medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, co-director of the Santa Monica-UCLA Outpatient Oncology Practices, and director of the Breast Cancer Clinical Trials Program at UCLA.
In an interview with OncLive
, these faculty discussed the potential impact of COVID-19 on patients with cancer.
Debu Tripathy, MD
: The impact of the rapid development of activities and events with the novel COVID-19 is unclear at this point. In our modern era, it is an interesting phenomenon to be involved in, in a virus that [is becoming] a pandemic.
... to read the full story